Literature DB >> 12216903

Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation.

Clarke E Atkins1, William A Brown, Julie R Coats, Mary Ann Crawford, Teresa C DeFrancesco, Joel Edwards, Philip R Fox, Bruce W Keene, Linda Lehmkuhl, Michael Luethy, Kate Meurs, Jean-Paul Petrie, Frank Pipers, Steven Rosenthal, Jennifer A Sidley, Justin Straus.   

Abstract

OBJECTIVE: To determine the effect of long-term administration of enalapril on renal function in dogs with severe, compensated mitral regurgitation.
DESIGN: Randomized controlled trial. ANIMALS: 139 dogs with mitral regurgitation but without overt signs of heart failure. PROCEDURE: Dogs were randomly assigned to be treated with enalapril (0.5 mg/kg [0.23 mg/lb], PO, q 24 h) or placebo, and serum creatinine and urea nitrogen concentrations were measured at regular intervals for up to 26 months.
RESULTS: Adequate information on renal function was obtained from 132 dogs; follow-up time ranged from 0.5 to 26 months (median, 12 months). Mean serum creatinine and urea nitrogen concentrations were not significantly different between dogs receiving enalapril and dogs receiving the placebo at any time, nor were concentrations significantly different from baseline concentrations. Proportions of dogs that developed azotemia or that had a +/- 35% increase in serum creatinine or urea nitrogen concentration were also not significantly different between groups.
CONCLUSIONS: And Clinical Relevance: Results suggest that administration of enalapril for up to 2 years did not have any demonstrable adverse effects on renal function in dogs with severe, compensated mitral regurgitation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12216903     DOI: 10.2460/javma.2002.221.654

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  4 in total

1.  Preliminary Investigation of Cardiovascular-Renal Disorders in Dogs with Chronic Mitral Valve Disease.

Authors:  E Martinelli; C Locatelli; S Bassis; S Crosara; S Paltrinieri; P Scarpa; I Spalla; A M Zanaboni; C Quintavalla; P Brambilla
Journal:  J Vet Intern Med       Date:  2016-09       Impact factor: 3.333

2.  Reliability of symmetric dimethylarginine in dogs with myxomatous mitral valve disease as kidney biomarker.

Authors:  Alice Savarese; Monica Probo; Chiara Locatelli; Sergio Aurelio Zanzani; Alessia Libera Gazzonis; Melissa Papa; Paola Giuseppina Brambilla
Journal:  Open Vet J       Date:  2018-08-19

Review 3.  The renin-angiotensin-aldosterone system and its suppression.

Authors:  Marisa K Ames; Clarke E Atkins; Bertram Pitt
Journal:  J Vet Intern Med       Date:  2019-02-26       Impact factor: 3.333

Review 4.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.